Miriam Martínez-Navarro1, David Cabañero1, Agnieszka Wawrzczak-Bargiela2, Anne Robe3,4,5,6, Claire Gavériaux-Ruff3,4,5,6, Brigitte L Kieffer3,4,5,6,7, Ryszard Przewlocki8, Josep E Baños1, Rafael Maldonado1,9. 1. Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain. 2. Department of Pharmacology, Laboratory of Pharmacology and Brain Biostructure, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. 3. Department of Translational Medicine and Neurogenetics, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch-Graffenstaden, Strasbourg, France. 4. IGBMC, Université de Strasbourg, Illkirch, France. 5. Laboratory UMR7104, Centre National de la Recherche Scientifique, UMR7104, Illkirch, France. 6. Unit U 1258, Institut National de la Santé et de la Recherche Médicale, U 1258, Illkirch, France. 7. Faculty of Medicine, Douglas Research Centre, McGill University, Montreal, Quebec, Canada. 8. Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. 9. Laboratory of Neuropharmacology, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
Abstract
BACKGROUND AND PURPOSE: Mu and delta opioid receptors(MOP, DOP) contribution to the manifestations of pathological pain is not understood. We used genetic approaches to investigate the opioid mechanisms modulating neuropathic pain and its comorbid manifestations. EXPERIMENTAL APPROACH: We generated conditional knockout mice with MOP or DOP deletion in sensoryNav1.8-positive neurons (Nav1.8), in GABAergic forebrain neurons (DLX5/6) orconstitutively (CMV). Mutant mice and wild-type littermates were subjected topartial sciatic nerve ligation (PSNL) or sham surgery and their nociception wascompared. Anxiety-, depressivelike behaviour and cognitive performance were also measured. Opioid receptor mRNA expression, microgliosis and astrocytosis were assessed in the dorsalroot ganglia (DRG) and/or the spinal cord (SC). KEY RESULTS: Constitutive CMV-MOP knockouts after PSNL displayed reduced mechanical allodynia and enhanced heat hyperalgesia. This phenotype was accompanied by increased DOP expression in DRG and SC, and reduced microgliosis and astrocytosis in deep dorsal horn laminae. Conditional MOP knockouts and control mice developed similar hypersensitivity after PSNL, except for anenhanced heat hyperalgesia by DLX5/6-MOP male mice. Neuropathic pain-induced anxiety was aggravated in CMV-MOP and DLX5/6-MOP knockouts. Nerve-injured CMV-DOP mice showed increased mechanical allodynia, whereas Nav1.8-DOP and DLX5/8-DOP mice had partial nociceptive enhancement. CMV-DOP and DLX5/6-DOP mutants showed increased depressive-like behaviour after PSNL. CONCLUSIONS AND IMPLICATIONS: MOP activity after nerve injury increased anxiety-like responses involving forebrain GABAergic neurons and enhanced mechanical pain sensitivity along with repression of DOP expression and spinal cord gliosis. In contrast, DOP shows a protective function limiting nociceptive and affective manifestations of neuropathic pain.
BACKGROUND AND PURPOSE: Mu and delta opioid receptors(MOP, DOP) contribution to the manifestations of pathological pain is not understood. We used genetic approaches to investigate the opioid mechanisms modulating neuropathic pain and its comorbid manifestations. EXPERIMENTAL APPROACH: We generated conditional knockout mice with MOP or DOP deletion in sensoryNav1.8-positive neurons (Nav1.8), in GABAergic forebrain neurons (DLX5/6) orconstitutively (CMV). Mutant mice and wild-type littermates were subjected topartial sciatic nerve ligation (PSNL) or sham surgery and their nociception wascompared. Anxiety-, depressivelike behaviour and cognitive performance were also measured. Opioid receptor mRNA expression, microgliosis and astrocytosis were assessed in the dorsalroot ganglia (DRG) and/or the spinal cord (SC). KEY RESULTS: Constitutive CMV-MOP knockouts after PSNL displayed reduced mechanical allodynia and enhanced heat hyperalgesia. This phenotype was accompanied by increased DOP expression in DRG and SC, and reduced microgliosis and astrocytosis in deep dorsal horn laminae. Conditional MOP knockouts and control mice developed similar hypersensitivity after PSNL, except for anenhanced heat hyperalgesia by DLX5/6-MOP male mice. Neuropathic pain-induced anxiety was aggravated in CMV-MOP and DLX5/6-MOP knockouts. Nerve-injured CMV-DOPmice showed increased mechanical allodynia, whereas Nav1.8-DOP and DLX5/8-DOP mice had partial nociceptive enhancement. CMV-DOP and DLX5/6-DOP mutants showed increased depressive-like behaviour after PSNL. CONCLUSIONS AND IMPLICATIONS: MOP activity after nerve injury increased anxiety-like responses involving forebrain GABAergic neurons and enhanced mechanical pain sensitivity along with repression of DOP expression and spinal cord gliosis. In contrast, DOP shows a protective function limiting nociceptive and affective manifestations of neuropathic pain.
Authors: G Corder; S Doolen; R R Donahue; M K Winter; B L Jutras; Y He; X Hu; J S Wieskopf; J S Mogil; D R Storm; Z J Wang; K E McCarson; B K Taylor Journal: Science Date: 2013-09-20 Impact factor: 47.728
Authors: Stephen P H Alexander; Arthur Christopoulos; Anthony P Davenport; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2019-12 Impact factor: 8.739
Authors: Claire Gaveriaux-Ruff; Chihiro Nozaki; Xavier Nadal; Xavier C Hever; Raphael Weibel; Audrey Matifas; David Reiss; Dominique Filliol; Mohammed A Nassar; John N Wood; Rafael Maldonado; Brigitte L Kieffer Journal: Pain Date: 2011-02-03 Impact factor: 6.961
Authors: David Cabañero; Alyssa Baker; Shengtai Zhou; Gregory L Hargett; Takeshi Irie; Yan Xia; Hélène Beaudry; Louis Gendron; Zara Melyan; Susan M Carlton; Jose A Morón Journal: Neuropsychopharmacology Date: 2013-02-12 Impact factor: 7.853
Authors: Carmen La Porta; S Andreea Bura; Jone Llorente-Onaindia; Antoni Pastor; Francisco Navarrete; María Salud García-Gutiérrez; Rafael De la Torre; Jorge Manzanares; Jordi Monfort; Rafael Maldonado Journal: Pain Date: 2015-10 Impact factor: 7.926
Authors: Miriam Martínez-Navarro; David Cabañero; Agnieszka Wawrzczak-Bargiela; Anne Robe; Claire Gavériaux-Ruff; Brigitte L Kieffer; Ryszard Przewlocki; Josep E Baños; Rafael Maldonado Journal: Br J Pharmacol Date: 2020-02-10 Impact factor: 8.739
Authors: Catherine M Cahill; Sarah V Holdridge; Shiwei Steve Liu; Lihua Xue; Claire Magnussen; Edmund Ong; Patrick Grenier; Anne Sutherland; Mary C Olmstead Journal: J Neurosci Res Date: 2020-07-05 Impact factor: 4.164